MiR-200c targets CDK2 and suppresses tumorigenesis in renal cell carcinoma

Molecular Cancer Research

Volumn 13, Issue 12, 2015, Pages 1567-1577

  Wang, Xuegang ^a,b   Chen, Xuanyu ^a   Han, Weiwei ^a   Ruan, Anming ^a   Chen, Li ^a   Wang, Rong ^a   Xu, Zhenghong ^c   Xiao, Pei ^c   Lu, Xing ^c   Zhao, Yan ^c   Zhou, Jia ^c   Chen, Shaoyong ^d   Du, Quansheng ^e   Yang, Hongmei ^c   Zhang, Xiaoping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d Division of Hematology and Oncology   (United States)

^e MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; MICRORNA 200C; 3' UNTRANSLATED REGION; CDK2 PROTEIN, HUMAN; MICRORNA; MIRN200 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOINFORMATICS; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GROWTH CURVE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; LUCIFERASE ASSAY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; 3' UNTRANSLATED REGION; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TUMOR; MALE; METABOLISM; PATHOLOGY; PROCEDURES; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 2; DOWN-REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICRORNAS; NEOPLASM TRANSPLANTATION;

EID: 84950321986     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0128     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. Redova M, Svoboda M, Slaby O. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem Biophys Res Commun 2011;405:153-6.
5. Hutson TE, Figlin RA. Novel therapeutics for metastatic renal cell carcinoma. Cancer 2009;115:2361-7.
6. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-Targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-9.
7. Nelson KM, Weiss GJ. MicroRNAs and cancer: past, present, and potential future. Mol Cancer Ther 2008;7:3655-60.
8. Bandyopadhyay S, Mitra R, Maulik U, Zhang MQ. Development of the human cancer microRNA network. Silence 2010;1:6.
9. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
10. Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, et al. Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol 2009;35:1119-23.
11. Juan D, Alexe G, Antes T, LiuH,Madabhushi A,Delisi C, et al. Identification of a microRNA panel for clear-cell kidney cancer. Urology 2010;75: 835-41.
12. Majid S, Saini S, Dar AA, Hirata H, Shahryari V, Tanaka Y, et al. MicroRNA-205 inhibits Src-mediated oncogenic pathways in renal cancer. Cancer Res 2011;71:2611-21.
13. Saini S, Yamamura S, Majid S, Shahryari V, Hirata H, Tanaka Y, et al. MicroRNA-708 induces apoptosis and suppresses tumorigenicity in renal cancer cells. Cancer Res 2011;71:6208-19.
14. Al-Ali BM, Ress AL,Gerger A, Pichler M. MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer Res 2012;32:3727-32.
15. Nakada C, Matsuura K, Tsukamoto Y, Tanigawa M, Yoshimoto T, Narimatsu T, et al. Genome-wide microRNA expression profiling in renal cell carcinoma: significantdown-regulation of miR-141 and miR-200c. J Pathol 2008;216:418-27.
16. Jung M, Mollenkopf HJ, Grimm C, Wagner I, Albrecht M, Waller T, et al. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy. J Cell Mol Med 2009;13:3918-28.
17. Yi Z, Fu Y, Zhao S, Zhang X, Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J Cancer ResClin Oncol 2010;136:855-62.
18. Weng L, Wu X, Gao H, Mu B, Li X, Wang JH, et al. MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens. J Pathol 2010;222:41-51.
19. Berkers J, Govaere O, Wolter P, Beuselinck B, Schoffski P, van Kempen LC, et al. A possible role for MicroRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-To-mesenchymal transition and hypoxia resistance. J Urol 2013;189:1930-8.
20. Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, et al. Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 2013;58:508-16.
21. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of Ecadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008; 283:14910-4.
22. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008;10:593-601.
23. Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, et al. microRNA-200c modulates the epithelial-To-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep 2013;30:643-50.
24. Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAILreceptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007;251:146-57.
25. Lu J, He ML, Wang L, Chen Y, Liu X, Dong Q, et al. MiR-26a inhibits cell growth and tumorigenesis of nasopharyngeal carcinoma through repression of EZH2. Cancer Res 2011;71:225-33.
26. Fang JH, Zhou HC, Zeng C, Yang J, Liu Y, Huang X, et al. MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression. Hepatology 2011;54:1729-40.
27. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget 2012;3:44-57.
28. Villerbu N, Gaben AM, Redeuilh G,Mester J. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer 2002;97:761-9.
29. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of protein kinase inhibitors: an update. Biochem J 2003;371:199-204.
30. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008;27:5959-74.
31. Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clin Cancer Res 2014;20:2617-30.
32. Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelialmesenchymal transition. Cancer Biol Ther 2010;10:219-22.
33. Hurteau GJ, Carlson JA, Spivack SD, Brock GJ. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res 2007;67: 7972-6.
34. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008;22:894-907.
35. Schickel R, Park SM, Murmann AE, Peter ME. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010;38:908-15.
36. Hamano R, Miyata H, Yamasaki M, Kurokawa Y, Hara J, Moon JH, et al. Overexpression of miR-200c induces chemoresistance in esophageal cancersmediated through activation of the Akt signaling pathway. Clin Cancer Res 2011;17:3029-38.
37. Hur K, Toiyama Y, Takahashi M, Balaguer F, Nagasaka T, Koike J, et al. MicroRNA-200c modulates epithelial-To-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut 2013;62:1315-26.
38. Yu J, Ohuchida K, Mizumoto K, Sato N, Kayashima T, Fujita H, et al. MicroRNA, hsa-miR-200c, is an independent prognostic factor in pancreatic cancer and its upregulation inhibits pancreatic cancer invasion but increases cell proliferation. Mol Cancer 2010;9:169.
39. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
40. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007;6:2127-32.
41. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
42. Li A, Blow JJ. The origin of CDK regulation. Nat Cell Biol 2001;3:E182-4.
43. Santamaria D, Barriere C,Cerqueira A,Hunt S, TardyC,NewtonK, et al.Cdk1 is sufficient to drive the mammalian cell cycle. Nature 2007;448:811-5.
44. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, et al. Cyclindependent kinase 2 is essential formeiosis but not formitotic cell division in mice. Nat Genet 2003;35:25-31.
45. Hydbring P, Larsson LG. Tipping the balance: Cdk2 enables Myc to suppress senescence. Cancer Res 2010;70:6687-91.
46. Campaner S, Doni M, Hydbring P, Verrecchia A, Bianchi L, Sardella D, et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010;12:54-9.